Greenwich LifeSciences Announces $2.5 Million Private Placement

STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company” or “Greenwich”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks